NCT06302465View on ClinicalTrials.gov

Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

December 31, 2026

Conditions
Malignant Bone Tumor
Interventions
DRUG

narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide

Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.

DRUG

doxorubicin、cisplatin、methotrexate、ifosfamide

doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER